Literature DB >> 9012593

Analysis of current trends in United States mesothelioma incidence.

B Price1.   

Abstract

Mesothelioma incidence often is interpreted as an index of past exposure to airborne asbestos. The mesothelioma rate for US males exhibits an increasing trend throughout the 1970s and early 1980s. The trend has been attributed to occupational exposure in the shipbuilding industry during World War II, in manufacturing, and in building construction. Incidence data (1973-1992) from the Surveillance, Epidemiology, and End Results Program were used to investigate current trends in age-adjusted and age-specific mesothelioma rates. An age and birth-cohort model was used to project both lifetime probabilities of mesothelioma by cohort and the annual number of cases expected over the next 70 years. The current trend in female rates is flat (age-adjusted rate = 0.30 per 100,000). The estimated lifetime risk for females is 2.5 x 10(-4), independent of birth cohort. The projected average annual number of female cases is 500. For males, the age-adjusted mesothelioma rate is increasing solely due to the age group 75 years and over, albeit at a declining growth rate. Lifetime risk for males peaks at 2 x 10(-3) for the 1925-1929 birth cohort, then decreases to 5 x 10(-4) for the 1955-1959 birth cohort. The pattern of rates reflected in the age and birth-cohort model suggests a peak in the annual number of mesothelioma cases for males at 2,300 before the year 2000. The number of male cases then will drop during the next 50-60 years toward 500. These trends mirror the US trend in raw asbestos consumption and a reduction in workplace airborne asbestos levels.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9012593     DOI: 10.1093/oxfordjournals.aje.a009093

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  54 in total

1.  Updated mortality among diverse operating segments of a petroleum company.

Authors:  R J Lewis; A R Schnatter; A M Katz; F S Thompson; N Murray; G Jorgensen; G Thériault
Journal:  Occup Environ Med       Date:  2000-09       Impact factor: 4.402

2.  Radical surgery for mesothelioma.

Authors:  Tom Treasure; David Waller; Simon Swift; Julian Peto
Journal:  BMJ       Date:  2004-01-31

3.  History of asbestos related disease.

Authors:  P W J Bartrip
Journal:  Postgrad Med J       Date:  2004-02       Impact factor: 2.401

4.  Distribution and trends in mesothelioma mortality in Italy from 1974 to 2006.

Authors:  M P Gatto; Di Tanna; G L Di Tanna
Journal:  Int Arch Occup Environ Health       Date:  2012-05-22       Impact factor: 3.015

Review 5.  Clinical presentation, diagnosis, classification and management of peritoneal mesothelioma: a review.

Authors:  Alfonso García-Fadrique; Akash Mehta; Faheez Mohamed; Sanjeev Dayal; Tom Cecil; Brendan J Moran
Journal:  J Gastrointest Oncol       Date:  2017-10

Review 6.  Malignant peritoneal mesothelioma: a review.

Authors:  Joseph Kim; Shanel Bhagwandin; Daniel M Labow
Journal:  Ann Transl Med       Date:  2017-06

7.  Frequent coamplification and cooperation between C-MYC and PVT1 oncogenes promote malignant pleural mesothelioma.

Authors:  Erick Riquelme; Milind B Suraokar; Jaime Rodriguez; Barbara Mino; Heather Y Lin; David C Rice; Anne Tsao; Ignacio I Wistuba
Journal:  J Thorac Oncol       Date:  2014-07       Impact factor: 15.609

8.  Future trends in mortality of French men from mesothelioma.

Authors:  A Banaei; B Auvert; M Goldberg; A Gueguen; D Luce; S Goldberg
Journal:  Occup Environ Med       Date:  2000-07       Impact factor: 4.402

Review 9.  Malignant peritoneal mesothelioma: a review.

Authors:  Glenn Broeckx; Patrick Pauwels
Journal:  Transl Lung Cancer Res       Date:  2018-10

10.  Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810).

Authors:  Sujith R Kalmadi; Cathryn Rankin; Michael J Kraut; Andrew D Jacobs; Daniel P Petrylak; David J Adelstein; Mary Louise Keohan; Robert N Taub; Ernest C Borden
Journal:  Lung Cancer       Date:  2007-11-19       Impact factor: 5.705

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.